Constitutive activation of STAT3 was observed in more than 50% of non-small-cell lung carcinoma (NSCLC) patients [27] and correlated with tumor lymph node metastasis, drug resistance, advanced clinical stage and low level of tumor differentiation [27,29,30,31]. Here, STAT3 is linked to non-small cell lung carcinoma.